ALTAltimmune, Inc.

$353M

Q3 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$2,000-98.7% YoY

Gross Profit

-$20M-1013000.0% margin

Operating Income

-$25M-1237600.0% margin

Net Income

-$24M-1175800.0% margin

EPS (Diluted)

$-0.48

QoQ Revenue Growth

-75.0%

Cash Flow

Operating Cash Flow

-$15M

Free Cash Flow

-$15M

Stock-Based Comp.

$2M

Balance Sheet

Total Assets

$225M

Total Liabilities

$20M

Stockholders' Equity

$205M

Cash & Equivalents

$127M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$2,000	$158,000	-98.7%
Gross Profit	-$20M	-$29M	+30.3%
Operating Income	-$25M	-$33M	+25.5%
Net Income	-$24M	-$34M	+29.8%

ALT Q3 2022 Earnings — Altimmune, Inc. Revenue & Financial Results | Market Cap Arena